Presentation for mHealth Israel by David Fegygin, VP of Health IT Integration and Strategic Innovation, Becton Dickinson, for mHealth Israel, July 14, 2015 in Tel Aviv
Presentation by Noel Harvey, VP R&D, and Al Lauritano, Head of Strategic Technology Partnerships, Becton Dickinson, on January 19, 2015 for mHealth Israel meetup.
Presentation by Noel Harvey, VP R&D, and Al Lauritano, Head of Strategic Technology Partnerships, Becton Dickinson, on January 19, 2015 for mHealth Israel meetup.
This is a Dean's Case Competition project in Som-Binghamton University. I did it with my team in Spring 2014 to present our the overall situation of Medtronic Inc.
mHealth Israel_Future of Integrated Individualized Healthcare_Roche DiagnosticsLevi Shapiro
Presentation by Alexandra Eberhard, Sr. Director, Global Business Development, Roche Diagnostics on the "Future of Integrated Individualized Healthcare". Includes background about Roche Diagnostics and investments in innovation. Overview of Roche products and solutions with a portfolio covering the entire spectrum of diagnostics users. Emphasis on the triple aim of healthcare- The power of data and technology to enable the transformation from volume- to value-based healthcare. Interest in data for Pharma - drive more efficient R&D; DIA - develop novel patient care Dx solutions. Focus on the needs of labs, physicians & payers for better patient health. A suite of digital solutions that improve clinical & business outcomes. Suite of solutions to optimize the lab. Translating data into insights to achieve financial goals. A move from volume- to value-based care. New opportunities in the disease continuum- Holistic solutions approach. Expanding the focus towards earlier in the patient journey. Doing now what patients need next. Contact Alexandra Vallon-Eberhard, PhD MBA; Sr. Director Global Business Development; Diagnostics Lead for Innovation in Israel; Based in Basel, Switzerland; Email: alexandra.vallon_eberhard@roche.com
US Healthcare Reimbursement for MedTech & Digital HealthLevi Shapiro
Overview of the US healthcare reimbursement framework as it relates to MedTech and Digital Health companies by David Farber, Senior Partner, King & Spalding law firm. Includes Introduction FDA Approval vs. Reimbursement; Different Standards; Clinical Evidence Needed; The Three Keys to Reimbursement Coverage; Coding; Payment; What’s New for 2019 Reimbursement for MedTech; AI Solutions Tips for Successful Reimbursement
mHealth Israel_E-Health to Digital Health_Jeremy Brody_Kantar HealthLevi Shapiro
Jeremy Brody, Chief Strategy Officer, Kantar Health (WPP) uses data to advise healthcare industry players about strategies for addressing major challenges such as Patient education, Compliance and adherence, Patient – physicians connectivity and communications, Patient records, Patient communities and support, Pharma value add, Disease management / population health management. They do this through their extensive healthcare database of projectable, self-reported, “real-world” patient-level information, covering over 165 therapeutic conditions and 1 million respondents. Key Trends include an ever changing patient physician dynamic; High health related app adoption; Fitness as a driver for wearables adoption; Transition from web connected to mobile connected devices; Low awareness of web / mobile connected devices; Physicians very slow to recommend connected devices;
Chris Cleary, Vice President of Corporate Development, Medtronic presented at MEDTECH 2014 on Fulfilling the Mission: Medtronic Embraces Change to Respond to an Evolving Healthcare Landscape.
2016 trends in global medical device strategy and issues for the supply chainTony Freeman
In its 2016 annual review of the global medical device supply chain Manning Advisors identifies two core trends driving both OEM and supplier strategy. The first trend, consolidation, has paused to allow integration of large acquisitions made in the last three years. The second trend, changing products to compete in a fee-for-value rather than fee-for-service reimbursement environment, drives new technologies and capabilities. These trends continue to redistribute favored firms in medical devices.
Global Trends in Medical Device and Diagnostic OEM Strategy and Implications ...Tony Freeman
Manning Advisors is pleased to announce the publication of its 2017 Global Trends in Medical Device and Diagnostic OEM Strategy and Implications for the Supply Chain. As in past years we looked at the major issues facing medical device OEMs and how those issues drive their relationship with their suppliers.
Our findings this year include:
Medical Device OEMs focusing on improved organic growth
2016 saw major OEMs relying heavily on acquisitions to improve revenues
OEMs see the eventual end of needle-moving acquisitions and are focusing on how to accelerate organic growth
Fee-for-value reimbursement and growing use of informatics are leading to redesign of product suites
The Supply Chain is consolidating around fewer, larger players
The supply chain is also consolidating via acquisitions
OEMs are embracing risk reduction by working with larger supply chain partners
The new threat to existing supply chain companies is the penetration of the market by giant global contract manufacturers like Flextronics and Celestica
Opportunity exists for smaller, nimble players who can assist OEMs in bring product to market more quickly
Opportunity also exists for specialized manufacturers
Feel free to contact me to discuss the issues or to arrange for an onsite presentation to your Board or management team. I look forward to an intriguing discussion.
You may reach me at tfreeman@manningadvisors.com or at (917) 868-0772 directly.
Best regards,
Tony Freeman, Managing Director
Manning Advisors LLC
90 Park Avenue, 17th Floor
New York, NY 10016
Q2 2015 ARM - Alliance for Regenerative Medicine
Quarterly Data Report: Q2 2015 provides an in-depth look at regenerative medicine and advanced therapies sector trends and metrics compiled from more than 580 leading therapeutic companies worldwide.
Trends in Global Medical Device OEM Strategies and Issues for the Medical Dev...Tony Freeman
Presented at the February, 2013 mdmX Conference, Manning Advisors' Tony Freeman reviews issues facing the largest medical device manufacturers and implications for their supply chain.
Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2015 | Five T...Mercer Capital
Mercer Capital provides medical device manufacturers, related start-up enterprises, and private equity funds with valuation services, including purchase price allocation, 409a compliance, goodwill impairment testing, and other transaction and valuation advisory services.
Health Policy Supporting Innovation in Korean Medical Device Sector (July 11,...Sung Yoon Bae
Presented in the AMCHAM Healthcare Innovation Seminar, held in Seoul, Korea on July 11, 2012.
Title: Toward Better Health Policy Supporting Innovation in Korean Medical Device Sector
Date: July 11, 2012
Speaker, Sung Yoon Bae, Professor of Healthcare Management, Inje University, Busan, Korea
These slides use concepts from my (Jeff Funk) course on Business Models at National University of Singapore to analyze the business model for Theranos. Theranos provides diagnostic testing for consumers that is faster and cheaper than the existing system. Its tests are done in easy to access pharmacies (e.g., Walgreens) as opposed to hard-to reach doctors’ offices. The tests use small bio-electronic integrated circuits (ICs) instead of large scientific instruments. These ICs utilize micro-fluidic channels that require a pin-prick of blood instead of a vial of blood, which makes the tests more appealing and faster than the traditional tests. The slides describe the value proposition, method of value capture, customers, scope of activities, and method of strategic control for Theranos.
Lessons for successfully executing digital transformation in HealthcareHenk Bakker
Many common perceptions about digital transformation are
actually myths. Fortunately, our global survey of nearly 400 large firms, supplemented by 157 in-depth interviews
with senior executives in more than 50 large companies, provides factbased answers.
This is a Dean's Case Competition project in Som-Binghamton University. I did it with my team in Spring 2014 to present our the overall situation of Medtronic Inc.
mHealth Israel_Future of Integrated Individualized Healthcare_Roche DiagnosticsLevi Shapiro
Presentation by Alexandra Eberhard, Sr. Director, Global Business Development, Roche Diagnostics on the "Future of Integrated Individualized Healthcare". Includes background about Roche Diagnostics and investments in innovation. Overview of Roche products and solutions with a portfolio covering the entire spectrum of diagnostics users. Emphasis on the triple aim of healthcare- The power of data and technology to enable the transformation from volume- to value-based healthcare. Interest in data for Pharma - drive more efficient R&D; DIA - develop novel patient care Dx solutions. Focus on the needs of labs, physicians & payers for better patient health. A suite of digital solutions that improve clinical & business outcomes. Suite of solutions to optimize the lab. Translating data into insights to achieve financial goals. A move from volume- to value-based care. New opportunities in the disease continuum- Holistic solutions approach. Expanding the focus towards earlier in the patient journey. Doing now what patients need next. Contact Alexandra Vallon-Eberhard, PhD MBA; Sr. Director Global Business Development; Diagnostics Lead for Innovation in Israel; Based in Basel, Switzerland; Email: alexandra.vallon_eberhard@roche.com
US Healthcare Reimbursement for MedTech & Digital HealthLevi Shapiro
Overview of the US healthcare reimbursement framework as it relates to MedTech and Digital Health companies by David Farber, Senior Partner, King & Spalding law firm. Includes Introduction FDA Approval vs. Reimbursement; Different Standards; Clinical Evidence Needed; The Three Keys to Reimbursement Coverage; Coding; Payment; What’s New for 2019 Reimbursement for MedTech; AI Solutions Tips for Successful Reimbursement
mHealth Israel_E-Health to Digital Health_Jeremy Brody_Kantar HealthLevi Shapiro
Jeremy Brody, Chief Strategy Officer, Kantar Health (WPP) uses data to advise healthcare industry players about strategies for addressing major challenges such as Patient education, Compliance and adherence, Patient – physicians connectivity and communications, Patient records, Patient communities and support, Pharma value add, Disease management / population health management. They do this through their extensive healthcare database of projectable, self-reported, “real-world” patient-level information, covering over 165 therapeutic conditions and 1 million respondents. Key Trends include an ever changing patient physician dynamic; High health related app adoption; Fitness as a driver for wearables adoption; Transition from web connected to mobile connected devices; Low awareness of web / mobile connected devices; Physicians very slow to recommend connected devices;
Chris Cleary, Vice President of Corporate Development, Medtronic presented at MEDTECH 2014 on Fulfilling the Mission: Medtronic Embraces Change to Respond to an Evolving Healthcare Landscape.
2016 trends in global medical device strategy and issues for the supply chainTony Freeman
In its 2016 annual review of the global medical device supply chain Manning Advisors identifies two core trends driving both OEM and supplier strategy. The first trend, consolidation, has paused to allow integration of large acquisitions made in the last three years. The second trend, changing products to compete in a fee-for-value rather than fee-for-service reimbursement environment, drives new technologies and capabilities. These trends continue to redistribute favored firms in medical devices.
Global Trends in Medical Device and Diagnostic OEM Strategy and Implications ...Tony Freeman
Manning Advisors is pleased to announce the publication of its 2017 Global Trends in Medical Device and Diagnostic OEM Strategy and Implications for the Supply Chain. As in past years we looked at the major issues facing medical device OEMs and how those issues drive their relationship with their suppliers.
Our findings this year include:
Medical Device OEMs focusing on improved organic growth
2016 saw major OEMs relying heavily on acquisitions to improve revenues
OEMs see the eventual end of needle-moving acquisitions and are focusing on how to accelerate organic growth
Fee-for-value reimbursement and growing use of informatics are leading to redesign of product suites
The Supply Chain is consolidating around fewer, larger players
The supply chain is also consolidating via acquisitions
OEMs are embracing risk reduction by working with larger supply chain partners
The new threat to existing supply chain companies is the penetration of the market by giant global contract manufacturers like Flextronics and Celestica
Opportunity exists for smaller, nimble players who can assist OEMs in bring product to market more quickly
Opportunity also exists for specialized manufacturers
Feel free to contact me to discuss the issues or to arrange for an onsite presentation to your Board or management team. I look forward to an intriguing discussion.
You may reach me at tfreeman@manningadvisors.com or at (917) 868-0772 directly.
Best regards,
Tony Freeman, Managing Director
Manning Advisors LLC
90 Park Avenue, 17th Floor
New York, NY 10016
Q2 2015 ARM - Alliance for Regenerative Medicine
Quarterly Data Report: Q2 2015 provides an in-depth look at regenerative medicine and advanced therapies sector trends and metrics compiled from more than 580 leading therapeutic companies worldwide.
Trends in Global Medical Device OEM Strategies and Issues for the Medical Dev...Tony Freeman
Presented at the February, 2013 mdmX Conference, Manning Advisors' Tony Freeman reviews issues facing the largest medical device manufacturers and implications for their supply chain.
Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2015 | Five T...Mercer Capital
Mercer Capital provides medical device manufacturers, related start-up enterprises, and private equity funds with valuation services, including purchase price allocation, 409a compliance, goodwill impairment testing, and other transaction and valuation advisory services.
Health Policy Supporting Innovation in Korean Medical Device Sector (July 11,...Sung Yoon Bae
Presented in the AMCHAM Healthcare Innovation Seminar, held in Seoul, Korea on July 11, 2012.
Title: Toward Better Health Policy Supporting Innovation in Korean Medical Device Sector
Date: July 11, 2012
Speaker, Sung Yoon Bae, Professor of Healthcare Management, Inje University, Busan, Korea
These slides use concepts from my (Jeff Funk) course on Business Models at National University of Singapore to analyze the business model for Theranos. Theranos provides diagnostic testing for consumers that is faster and cheaper than the existing system. Its tests are done in easy to access pharmacies (e.g., Walgreens) as opposed to hard-to reach doctors’ offices. The tests use small bio-electronic integrated circuits (ICs) instead of large scientific instruments. These ICs utilize micro-fluidic channels that require a pin-prick of blood instead of a vial of blood, which makes the tests more appealing and faster than the traditional tests. The slides describe the value proposition, method of value capture, customers, scope of activities, and method of strategic control for Theranos.
Lessons for successfully executing digital transformation in HealthcareHenk Bakker
Many common perceptions about digital transformation are
actually myths. Fortunately, our global survey of nearly 400 large firms, supplemented by 157 in-depth interviews
with senior executives in more than 50 large companies, provides factbased answers.
Business Model Innovation in Healthcare by Chris WasdenMatt Perez
Rapid technological advances, regulatory reform, and the new science of personalized medicine are the three primary factors driving unprecedented levels of innovation in the healthcare industry. These factors are forcing convergence among all members of the healthcare ecosystem in ways that enable all members to create greater value through extensive coordination, collaboration, and competition. Increasingly, providers, payers, products, and patients are leveraging mobile information technology to participate in M2M (mobile-to-mobile) digital healthcare delivery. Some of the key questions facing healthcare organizations, and particularly their CIOs, are: Where in the healthcare innovation ecosystem should we focus? What types of innovations create the most value for our organization? How do we enable greater levels of innovations from a strategic, process, and infrastructure perspectives? What are the barriers to developing and adopting innovation in the healthcare industry, and within healthcare organizations, and how do we overcome these barriers?
Healthcare and Digital Transformation - Lessons from the ResearchStefan Tornquist
A 30 minute talk based on survey research conducted in Q4 of 2015 w/Ogilvy CommonHealth on how digital trends are affecting healthcare and healthcare marketing.
Personal Data Tracking and the Digital Transformation of HealthcareLarry Smarr
12.12.05
Invited Talk
University of Illinois Silicon Valley Round Table
Title:Personal Data Tracking and the Digital Transformation of Healthcare
Palo Alto, CA
Digitale Transformation in der öffentlichen VerwaltungSven Ruoss
Digitale Transformation in der Schweiz - Lernen von den Besten - Digitale Schweiz 2020 - 5 Thesen zu Öffentliche Verwaltung goes Digital - Key Takeaways
Christina Wanscher presents an introduction to the Danish Healthcare system, healthcare transformation initiatives, National Healthcare IT and Integrated Care.
Details on the presentation found in link:
http://www-01.ibm.com/software/city-operations/curam-research-institute/curam-roundtable/index.html
The Digital Explosion—Driven by the Cloud: What’s Your Enterprise Strategy?Capgemini
Capgemini’s research with MIT demonstrates that the digital enterprise enjoys major competitive advantages—not only does it grow faster but it is also more profitable.
So what is a digital enterprise? How do you embrace business technology? How do you make the cloud your business cloud? How do you digitally transform?
This presentation the new roles of digital technology for and with business.
Originally presented at Oracle OpenWorld 2014 by Capgemini Fellow Pierre Hessler.
The FDA Digital Health Center of Excellence and the Advancement of Digital He...Greenlight Guru
The FDA Digital Health Center of Excellence is part of the planned evolution of the digital health program with the intent to drive synergy for digital health efforts, align strategy with implementation, prepare the FDA for the digital health future, and protect patients and maintain the FDA standards of safety and effectiveness.
Ultimately, the program works to strategically advance science and evidence for digital health technologies that meets the needs of
stakeholders.
This free in-depth webinar, presented by Matthew DiamondChief Medical Officer, Digital Health Center of Excellence, will cover the digital health landscape and areas of application, goals and outcomes, planned services and launch plan, and the current areas of focus - including AI/ML-Based SaMD.
This presentation originally aired during the 2021 State of Medical Device Virtual Summit.
As the author of “Big Data in Healthcare Hype and Hope,” Dr. Feldman has interviewed over 180 emerging tech and healthcare companies, always asking, “How can your new approach help patients?” Her research shows that data, as an enabling tool, has the power to give us critical new insights into not only what causes disease, but what comprises normal. Despite this promise, few patients have reaped the benefits of personalized medicine. A panel of leading big data innovators will discuss the evolving health data ecosystem and how big data is being leveraged for research, discovery, clinical trials, genomics, and cancer care. Case studies and real-life examples of what’s working, what’s not working, and how we can help speed up progress to get patients the right care at the right time will be explored and debated.
• Bonnie Feldman, DDS, MBA - Chief Growth Officer, @DrBonnie360
• Colin Hill - CEO, GNS Healthcare
• Jonathan Hirsch - Founder & President, Syapse
• Andrew Kasarskis, PhD - Co-Director, Icahn Institute for Genomics & Multiscale Biology; Associate Professor, Genetics & Genomic Studies, Icaahn School of Medicine at Mt. Sinai
• William King - CEO, Zephyr Health
New York eHealth Collaborative Digital Health Conference
November 18, 2014
HealthSaaS Overview Deck October 2014 (RPM, Home Health)HealthSaaS, Inc.
The HealthSaaS Connected Outcomes Platform removes silo barriers to connect, aggregate and integrate disparate data from mHealth applications and Remote Patient Monitoring (RPM) devices.
Our services provide HIPAA secure data to the “point of care” wherever the clinician is located. Enabling clinicians to rapidly respond to clinically relevant patient health information can facilitate early interventions, reduce hospital admissions, improve outcomes and lower costs.
Our passion empowers us to create eHealth collaboration tools that enhance provider efficiencies, track outcomes and improve the quality of life for patients throughout the continuum of care.
Access the webinar: http://goo.gl/p08pTz
These slides were presented in a webinar by Denodo in collaboration with BioStorage Technologies and Indiana Clinical and Translational Sciences Institute and Regenstrief Institute.
BioStorage Technologies, Inc., Indiana Clinical and Translational Sciences Institute, and Regenstrief Institute (CTSI) have joined Denodo to talk about the important role of technological advancements, such as data virtualization, in advancing biospecimen research.
By watching this webinar, you can gain insight into best practices around the integration of biospecimen and research data as well as technology solutions that provide consolidated views and rapid conversions of this data into valuable business insights. You will also learn how data virtualization can assist with the integration of data residing in heterogeneous repositories and can securely deliver aggregated data in real-time.
Data-driven Healthcare for ManufacturersLindaWatson19
Medical Device Equipment and Hospital Supplies Manufacturers also face increased pressure to comply with strict regulatory procedures to ensure patient safety. Product transparency and efficient end-to-end processes that optimize the manufacturing process and decision making are very important.
Data-Driven Healthcare for Manufacturers Amit Mishra
Data-driven healthcare empowers the providers with a common data platform to discover untapped data-driven opportunities. Healthcare data and its impact on the patient care decision process via accurate, real-time, reliable data from disparate sources is creating a digital health revolution. Physician groups, nursing facilities, hospitals, pharmaceutical companies, clinical researchers, and medical equipment manufacturers are all churning out vast amounts of data during their daily operations. This data has tremendous value and can revolutionize patient care, diagnosis, real-time decisions and help deliver new, unimagined innovations with quality of patient care. Know more about data-driven healthcare at https://www.solix.com/solutions/data-driven-solutions/healthcare/
Taking cognitive/ emotional assessments and therapies to scaleSharpBrains
Three digital health entrepreneurs–who have collectively raised over $75 million in venture capital in the last 18 months– and an investor discussed their respective visions and approaches to revolutionize brain and mental health in areas such as ADHD, substance abuse, and general brain fitness.
--Chair: Rita Carter, Science writer and BBC Contributor
--Edward Kliphuis, Investment Director at Merck Ventures
--Dr. Eddie Martucci, CEO of Akili Interactive Labs
--Dr. Corey McCann, CEO of Pear Therapeutics
Learn more at sharpbrains.com
According to a 2016 Nature survey, more than 70% of researchers have failed to reproduce another scientist’s experiments. To solve the reproducibility problem, the research community demands high-quality biobanks to deliver fit-for-purpose biospecimens – key pillars advancing science in medicine. Precision for Medicine is a global leader in supplying diverse, high quality, IRB-approved, clinically annotated, ready-to-ship human biospecimens.
This talk provides an insider’s look into Precision for Medicine’s variant-rich biobank showcasing biospecimen types, highlighting usage, custom collection solutions and disease-matched control sets across multiple therapeutic areas. Precision for Medicine’s biorepository contains diverse, genetically characterized specimens validated using various NGS assays and platforms.
Described in this talk are just some of the sample types, screening methods, and subsequently the integrated QuartzBio database of variants found. The speakers also discuss Precision for Medicine’s partnership capabilities, such as for supporting companion diagnostic development including inter-laboratory reproducibility, validation kit assembly and prospective collections for matched tissue types, minimal residual disease, and clinical trial enrollment.
Key Topics Include:
- Gain a broad understanding of Precision for Medicine, Biospecimen Solutions variant-rich biobank contents pertaining to different therapeutic areas
- Become familiar with fit-for-purpose human biospecimens, their diverse types and appropriate uses
- Become acquainted with the biospecimen characterization data available from Precision for
Medicine, Biospecimen Solutions
- Discover the various partnership options for sample and patient screening for R&D and CDx development and clinical trial enrollment
Tate Campbell, Change Healthcare - Extracting Knowledge from Healthcare Data ...Sri Ambati
This session was recorded in San Francisco on February 5th, 2019 and can be viewed here: https://youtu.be/Bd7Y2tGKgys
Tate Campbell is a Data Scientist at Change Healthcare specializing in Big Data and Cloud Technologies. Tate has experience as a practicing Data Scientist in the healthcare, legal, and marketing industries. Tate studied biochemistry and mathematics at California State University, Chico and holds a Master’s degree in Analytics from the University of San Francisco.
Michigan HealthTech Market Map 2024. Includes 7 categories: Policy Makers, Academic Innovation Centers, Digital Health Providers, Healthcare Providers, Payers / Insurance, Device Companies, Life Science Companies, Innovation Accelerators. Developed by the Michigan-Israel Business Accelerator
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...Levi Shapiro
Letter from the Congress of the United States regarding Anti-Semitism sent June 3rd to MIT President Sally Kornbluth, MIT Corp Chair, Mark Gorenberg
Dear Dr. Kornbluth and Mr. Gorenberg,
The US House of Representatives is deeply concerned by ongoing and pervasive acts of antisemitic
harassment and intimidation at the Massachusetts Institute of Technology (MIT). Failing to act decisively to ensure a safe learning environment for all students would be a grave dereliction of your responsibilities as President of MIT and Chair of the MIT Corporation.
This Congress will not stand idly by and allow an environment hostile to Jewish students to persist. The House believes that your institution is in violation of Title VI of the Civil Rights Act, and the inability or
unwillingness to rectify this violation through action requires accountability.
Postsecondary education is a unique opportunity for students to learn and have their ideas and beliefs challenged. However, universities receiving hundreds of millions of federal funds annually have denied
students that opportunity and have been hijacked to become venues for the promotion of terrorism, antisemitic harassment and intimidation, unlawful encampments, and in some cases, assaults and riots.
The House of Representatives will not countenance the use of federal funds to indoctrinate students into hateful, antisemitic, anti-American supporters of terrorism. Investigations into campus antisemitism by the Committee on Education and the Workforce and the Committee on Ways and Means have been expanded into a Congress-wide probe across all relevant jurisdictions to address this national crisis. The undersigned Committees will conduct oversight into the use of federal funds at MIT and its learning environment under authorities granted to each Committee.
• The Committee on Education and the Workforce has been investigating your institution since December 7, 2023. The Committee has broad jurisdiction over postsecondary education, including its compliance with Title VI of the Civil Rights Act, campus safety concerns over disruptions to the learning environment, and the awarding of federal student aid under the Higher Education Act.
• The Committee on Oversight and Accountability is investigating the sources of funding and other support flowing to groups espousing pro-Hamas propaganda and engaged in antisemitic harassment and intimidation of students. The Committee on Oversight and Accountability is the principal oversight committee of the US House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X.
• The Committee on Ways and Means has been investigating several universities since November 15, 2023, when the Committee held a hearing entitled From Ivory Towers to Dark Corners: Investigating the Nexus Between Antisemitism, Tax-Exempt Universities, and Terror Financing. The Committee followed the hearing with letters to those institutions on January 10, 202
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
mHealth Israel_Healthcare Finance and M&A- What Comes NextLevi Shapiro
Healthcare Finance and M&A, What Comes Next? Presentation by Matthew R. Kittay, National Co-Chair, M&A Practice Group, Fox Rothschild LLP. Includes fundraising and investments. Breakouts by subsector- Healthcare (overall), Healthcare services, Digital health, Biopharma, Pharmatech, Medtech, Healthcare IT. Healthcare transaction distribution breakouts. Exits remain flat. Avoiding common legal pitfalls like IP, compliance, governance structure. Current legislation in health law. IP strategy for healthtech.
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...Levi Shapiro
Oppenheimer & Co. Inc, co-Head of Healthcare Investment Banking, Michael Margolis, provides H1 Healthcare Financing, Funding and M&A Overview. Table of Contents
1. Broader Market Overview
2. Biotech M&A Market Overview
3. Private Biotech Financing Market Update
4. Key Advice For Healthcare Companies
Current State of Play; Healthcare has Underperformed the Broader Market Over the Last Twelve Months; Signal-to-Noise is Getting Worse; Healthcare IPO Activity has Decreased Significantly Since 20–21 Pandemic Levels; Biotech Financing Activity Has Remained Robust in 2024; Biotech M&A Market Remains Incredibly Active; Biotech M&A Market Remains Incredibly Active; Big Pharma Upcoming Patent Expirations; Since November 2023 Oncology has accounted for over half of all M&A; Oncology, Autoimmune / I&I, and CV & Metabolic Remain the Top Areas in M&A; Small Molecule Beats Out All Other Modalities in M&A Despite IRA Concerns; Value of Big Pharma Acquisitions by Therapeutic Area in Q1 2024; Private Financing Market Update; 2024 Private Placement Activity On Track to Approach, If Not Exceed, 2020 Levels; Oncology, Particularly Solid Tumor, Continues to Attract VC Investors; Despite the IRA, Small Molecules Continue to Attract VC Dollars; Preclinical-Stage Companies Make Up Almost Half of Private Placements in 2023; Valuations by Development Stage – 2023; Typical Biotech Investors Remained Active in Q1 2024; 23 $100M+ Deals were Raised in Q1 2024; Biotech Fundraising Momentum Continued into 2024; Key Advice For Israeli Healthcare Companies; Although Israel has Strong Presence on US Public Markets, There is Room to Grow; Telling Your Story Effectively; Interacting with Investors to Build Long-term Credibility; Seven Simple Rules for Pitch Decks;
Version Bravo- The Springboard for Navy SEAL entrepreneurship, cohort 003Levi Shapiro
Description of the Version Bravo intensive entrepreneurial launch program for 7 Israeli and 7 US former Navy SEALs. Details about each startup concept, the CEOs, the sector, etc.
Radical Life Extension_Dr. Leon Peshkin_Dec 2023Levi Shapiro
Presentation for mHealth Israel by Dr. Leon Peshkin, Harvard Medical School, exploring research into Embryology and Longevity, emphasizing Germline and protein aggregates. Includes current overview, anti aging through history, Lifespan Expansion, ALEC: Animal Life Expectancy in Controls, Scalable Platform in Pharmacobiology, Embryos Cleanse Protein Aggregates, Lysosomal switch triggers proteostasis renewal, Xenopus, Rejuvenation Roadmap, Citizen Science Approach to Aging, Xenopus: Maternal Dowry Molecules, Human Disease Modeling
Israel’s Life Science Hub 2023 English Abstract.pdfLevi Shapiro
The war between Israel and Hamas brings its own set of business
challenges. Challenges that may impact how we communicate with
partners and investors abroad. We should portray the life science sector as resilient and adaptable, even in times of crisis. This document is a a messaging outline for Israel's Life Science Hub despite the war with Hamas. Four key points to emphasize:
1) Global activity (resilience and agility)
2) Continuity of care and preventive medicine
3) World leading clinical trials industry
4) Dynamic scientific, research and entrepreneurial ecosystems
Gil Bashe FINN Partners: The Future of Digital Health – Nose Dive or Transfor...Levi Shapiro
The Future of Digital Health – Nose Dive or Transformation, by Gil Bashe, Dec 4th, 2023 at the mHealth Israel conference. Digital Health Innovation Ecosystem Investment Trends. Data & Methodology. Digital Health Taxonomy. Key Insights for Digital Health Innovation in H1 2023. Global Digital Health Funding Across Regions. Funding in North America. Shifting Focus in North America Digital Health Funding. Investment Focus for Digital Health Venture Funding. Ventures are turning to partnerships for proof points, scale and funding. 2022 new partnerships. North America digital health investor participation. Most active partners in North America. North America Ecosystem Development. Venture distribution by stage. Funding distribution. Comparison to 2022 Funding. Noteworthy deals, noteworthy exits.
Urgent Request and Call for Action for Ensuring Safety and Inclusivity at MITLevi Shapiro
We, 465 MIT Alumni, Staff, and Students, are writing to express our deep concern, fear, and disappointment regarding the recent protest that took place Thursday afternoon, in front of the MIT Stratton Student Center. While we fully support the principles of free
speech and the right to peaceful assembly, it is essential that we also prioritize the safety and well-being of all members of the MIT
community.
During the protest, a particular slogan was prominently displayed and chanted, which has raised significant concerns. The slogan
"From the [Jordan] river to the [Mediterranean] sea, Palestine will be free!" has been a source of contention due to its potential
implications and the real safety risks it poses to Jewish and Israeli students on campus [See video footage attached]. This slogan
has been time and again associated with calls for the destruction of the State of Israel and has been used in contexts that
promote violence, which raises legitimate concerns about the safety and security of our Jewish and Israeli students and staff.
Furthermore, we would like to draw your attention to recent events that demonstrate the potential dangers associated with this
slogan. During the 2023 Israel-Hamas war, British Home Secretary Suella Braverman proposed criminalizing the use of the slogan
in certain contexts, recognizing the potential harm it can cause. Additionally, on October 11, ‘23, Vienna police banned a
demonstration, citing the inclusion of the phrase "from the river to the sea" in invitations, as it was seen as a portrayal of a violation
of Article 2 of the European Convention on Human Rights.
In addition to the use of these derogatory messages, several attendees of the event used hateful wordings and messages towards
Jewish and Israeli bystanders. In one case, a perpetrator aggressively held their bicycles as intended to harm a Jewish MIT student,
stating that “[your] ancestors did not die in the Holocaust so they could kill Palestinians” [See video footage attached]. In another
incident, protesters chanted “one solution, intifada revolution”. In the context of the on-going Israeli-Palestinian conflict, the word
"Intifada" means the armed and violent Palestinian insurrection targeting Israelis, including civilians, which resulted in the killing of
thousands of Israelis in the last few decades.
On Oct. 22nd, a statement by MIT CAA (Coalition Against Apartheid) came to our attention. In this document, MIT CCA states that
they "hold the Israeli regime responsible for all unfolding violence". They later call the October 7th terror attack a "response to
the settler colonial regime", and continue justifying it throughout the document.
In this matter, MIT CAA is justifying the heinous and barbaric crimes committed on Oct 7th. Furthermore, these statements have the
potential to fuel acts of aggression
Overview of the Israeli exhibitors at the 2023 HLTH conference in Las Vegas. Exhibitors included 6Degrees, AppScent, Belong.Life, Datos, Expecting, IntraPosition, Kahun Medical, Kemtai, Maverick, Neteera, QuantaIX, Respiration Scan, Nerivio, Xoltar.
40% of Israeli technology investment is devoted to Life Science. Within that domain, the largest sector is Medical Devices and Digital Health (over 65 percent of companies). In the medical device arena, Israeli scientists and engineers have integrated advanced technologies in electronics, communications and electro-optics to develop world-class innovations in Digital Imaging, Medical Lasers, Telemedicine, Early Diagnostics,
Smart Surgical Equipment and more. Over 600 medical device exporters engaged in a variety of medical application
such as Cardiovascular and Peripheral Vascular, Neurology and Degenerative Diseases, Preparedness and Emergency
Medicine, Intensive Care, Women Health, Orthopedics and Sport Medicine, Gastrointestinal, Infection Control, Ophthalmology, Pain and Wound Management, Oral and Dental Care, Dermatology and Aesthetics
Baptist Health- Engineering the Future of HealthcareLevi Shapiro
Presentation by Mark Coticchia, Chief Innovation Officer, Baptist Health, for mHealth Israel community, September, 2023. Baptist Health has internationally renowned centers of excellence in cancer, cardiovascular care, orthopedics and sports medicine, and neurosciences.
A not-for-profit organization supported by philanthropy and committed to its faith-based charitable mission of medical excellence, Recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World’s Most Ethical Companies.Innovation is paramount to health system’s performance and reputation.
Becker’s 2019 Advisory Board survey revealed innovation and technology ranked as the top priority among healthcare finance professionals - up from eighth in 2018. 90% healthcare/life science leaders agree that the pandemic will fundamentally change the way they do business, requiring new products, services, processes, and business models (McKinsey: Innovation Through Crisis Survey). Innovation has been proven to help health systems in many ways. A capability and culture of innovation accomplish numerous goals:
Innovation capability and culture improve the care and work environment. They enhance the reputation through recognition for discoveries made at and through Baptist Health. They aid in the recruitment and retention of top talent. And they help systems harness money that otherwise would be leaving the system – licensing revenues and investment returns and corporate research support and donor revenues. Successful Programs - Common Underpinnings. Innovation as a strategic, institutional priority
Program built on institutional assets and centers of excellence
Experienced, professional team
Technology development and sourcing, Dedicated, long term support. Doing healthcare innovation well at a large enterprise takes a highly specialized team and skill set. Collectively, they need to have deep knowledge of healthcare regulation, medical procedures, patient safety, business development, transactions, business law, innovation markets, entrepreneurship, venture capital, commercialization, tech transfer, organizational change management, and much more. Programs- services, technology management, corporate co-creation, global medical service lines and facilities; Focus on market opportunity vs. technology; Select & concentrate on winners; Operate as a business; Proactive in new company formation; Progress, milestones, preliminary results; Building New Innovation Pathways; Improving Treatment for Cancer Patients; Predicting & Preventing Heart Attacks; Improving Outcomes in Cardiac Care; Enhancing a Culture of Innovation at Baptist Health & South Florida; Cleerly, TriVentures, COTA; Innovation is paramount to health system’s performance and reputation.
Baptist Health has established an innovation function predicated on best practices and tailored to its assets and the opportunities extending from Miami’s economic growth
YEDA Techn Transfer at Weizmann Institute- Discord and Challenges in Academic...Levi Shapiro
Presentation by Yael Klionsky, YEDA, for the mHealth Israel community in September, 2023. Title: Challenges in Academic Technology Transfer. Examples-
Transplantation Immunology and Immunometabolism. Efranat Pharma was developing an anticancer immunotherapy treatment based on a natural plasma protein molecule. From target discovery to clinical validation. Clinical-stage drug discovery and development company utilizing a broadly applicable, predictive
computational discovery platforms to identify novel drug targets and new biological pathways and develop
therapeutics in the field of cancer immunotherapy. To allow SOCIETY to benefit from discoveries made at the academic institution. To enable SCIENTISTS to transfer their new technologies to the market. To create an additional source of INCOME for the INSTITUTE so that more independent research can be conducted. Three important elements that make an idea patentable:
1) The invention must be new: the same idea can’t have been
published before in any form; 2) There must be some inventive step of ‘non-obviousness’.
This can be hard to define and depends on the context; 3) The disclosure in a patent must be sufficient for a skilled
person to reproduce the invention with only routine effort; Technology Transfer Company - modus operandi; OUR PURPOSE- To provoke transformative scientific breakthroughs that will shape the future of humanity; SCIENTIFIC STAFF- 300 Principal investigators, >2,000 Research students and PhDs; 5 FACULTIES – BASIC SCIENCE, Biology, Physics, Biochemistry, Math/CS
Chemistry; Generated IP- 57% in Life Science & Biotech; Among the Highest
Income per Researcher
Worldwide; 1959 (First TTO outside the US); Today- More applications per PI than in most Ivy league universities; Copaxone- >$30B
ANNUAL SALES BASED ON Weizmann IP; 20 new licenses per year and 10 new companies per annum; www.yedarnd.com
HADASIT: Tech Transfer and More in Life ScienceLevi Shapiro
Overview of activities in Life Science of Hadasit, the technology transfer arm of Hadassah Hospital in Jerusalem. Includes details about Jerusalem Biodesign program; spinouts like Brainwatch; details about tech transfer (the Secret Engine Behind Israel’s Success); relationship and examples of TTOs enabling Israel's greatest success stories; contrasting of Adademia (Scientific driven research, Creation of new knowledge, Publication, Sharing of Material, Social responsibilities) and Industry (Applied research & specific objectives, Develop new products, Product development, Secrecy and patent protection, Organization responsibilities); Development gap between initial inventions and product development; the Art of translation (from academic research to medical companies); Tech transfer transforms cutting-edge research into marketable healthcare technologies; LICENSING TO EXISTING COMPANIES; SPINNING OFF STARTUPS; CO-DEVELOPMENT OF JOINT IP; Technology Transfer Offices from Academia/Research Hospitals – to Industry; Overview of Hadassah and Hadasit (TECHNOLOGY TRANSFER COMPANY AND INNOVATION ENGINE OF HADASSAH UNIVERSITY HOSPITALS); Examples of “HADASSAH MADE” PRODUCTS IN THE GLOBAL MARKET; RECENT TECH TRANSFER SUCCESS; Example- Lineage Exclusive Worldwide Collaboration with Genentech Opregen® RPE Cell Therapy for the Treatment of Ocular Disorders; HADASIT PILLARS-
NURTURING INTERNAL INNOVATION, Tech Transfer, EXTERNAL INNOVATION. External- SERVICES & COLLABORATIONS WITH COMPANIES, BIOHOUSE FOR STARTUPS, DIGITAL HEALTH ACCELERATOR); Internal Innovation- NURTURING INTERNAL INNOVATION, HADASSAH SEED FUND, JERUSALEM BIODESIGN PROGRAM; TYPES OF RELATIONS WITH EXTERNAL COMPANIES- CONSULTING, SAB, CLINICAL TRIALS, R&D SERVICES, DATA LICENCE, ALPHA/BETA SITE, PILOTS, DESIGN PARTNERSHIPS.
Presenting to Investors & the Media.pdfLevi Shapiro
Presenting to Investors and the Media, lecture by Drew Levinson, LifeSci Communications to mHealth Israel. Three sections: Making a good presentation, Handling
interviews with reporters and Answers that resonate. PRESENTING TO INVESTORS AND THE MEDIA- Compelling delivery, Commanding a room, • Lasting Impact. A good presentation includes Information, Motivation and Excitement. Never put them to sleep. Audience impact includes content, credibility and delivery. Decisions are made leading to potential partnerships, winning business, so much more than a deck, your business, your brand, you. How to captivate begins with storytelling and conversation. More than features- benefits, humanize, positive impact. Don't complicate your message with jargon. Feel the passion- contagious, vision, determination. Know your audience- who are they, what do they know about you, how much do they know, interests, concerns. Articulate your vision- see it, feel it, believe in it. Take them on your journey- compelling narrative, make it personal, why are you doing this, inspiration. Your team- experienced, knowledgeable, aligned, execute. Risks and challenges- recognize, address, plan to mitigate. Test drive your room. What does it look like? Where is the podium? Where will I be standing? Where will you be sitting? Feel comfortable. Three parts to attention. The beginning- attention, interest, what's in it for them, entusiasm, preview. The middle- core, insights, challenges, solutions, relatable. The ending- summary, reinforce, messages, benefits, call to action, keep the momentum going. How to answer questions. The Four R's: repeat, reinforce, refer, remember. Talking to reporters- necessity; Good interview can enhance reputation; Bad interview can tarnish reputation; Preparation is vital. Shapes public opinion: Elevates your brand; Establishes authority; Showcases your business; A bridge; Reputation; Trust; Visibility. Know the reporter. Audience; What have they written; Previous stories; Questions asked. Concise- clear, succinct, engaging. Make it relatable: Stories; Anecdotes; Experiences; Examples; Metaphors; Connect. Honesty and transparency. It is okay not to know every answer. You don’t have to answer every question. Control the narrative. What not to do when talking to reporters. Come up with another way to say no comment. What to wear- solid colors, blues and grays, nothing distracting. Expertise, passion, vision, lasting impression, connections. High stakes, high rewards. Preparation; Know your audience; Deliver with confidence; Enthusiasm; Authenticity. Begin the journey. Engage in dialogue; Build relationships; Inspire trust and confidence; Valued; Enlightened; Motivated and excited.
Nissan Elimelech, Founder, Augmedics: How I Built the World's First XR Surgic...Levi Shapiro
Presentation by Nissan Elimelech, Founder, Augmedics: How I Built the World's First XR Surgical Navigation Company and What's Next for XR. Covers the company founding across multiple milestones and key success factors.
Beyeonics CEO, Ron Schneider, Advances in Medical XRLevi Shapiro
Overview by Beyeonics CEO, Ron Schneider, about the company. Beyeonics One is the first ophthalmic exoscope with an augmented reality surgical headset. It is a high-definition, fully digital imaging platform enabling surgeons to see a magnified, three-dimensional (3D) image of the surgical field. The small footprint, the fast setup, automation, and zero turnover time between procedures all contribute to the efficiency operating rooms strive for. Over 3000 cases to date. Unconstrained Movement. Unconstrained workflow. Data connectivity. Designed for continuous innovation.
XRHealth is revolutionizing healthcare, bringing patient care into the Metaverse. Includes a description of the TeleHealth Platform. Lessons Learned – Building the clinical Metaverse. Last mile delivery
Building a product in the Metaverse is easy – getting people to use it is hard. Virtual Care can’t be based only on XR. HMDs bring friction – Charging, Guardian, Safety, Passwords etc. Expanding virtually in a brick & mortar payer environment. Once you cross the chasm – adherence/ satisfaction/retention goes ballistic. Patient Outcomes-
Patients report significant improvement in symptoms following treatment. Adherence - patients follow Home Exercise Plans as prescribed. 92.2% with XRHealth vs 50% with regular treatment. Patient satisfaction - 85 NPS vs 38 NPS in healthcare
93.3% patient retention -complete treatment cycle as prescribed. XRHealth Luna AI Reduces Hot Flashes and Improves Psychological Well-Being in Women with Breast and Ovarian Cancer: A Pilot Study. Virtual reality immersion compared to monitored anesthesia care for hand surgery: A randomized controlled trial. Lessons Learned – Autism Spectrum Disorder. The future of the Mediverse.
Digital Health in US Health Systems.pptxLevi Shapiro
April, 2023 presentation by Gil Bashe, Global Chair, Health Practice, FINN Partners. Insights and analytics, in collaboration with Galen Growth, tracking Digital Health collaboration, adoption, integration, and best practices across the leading US Health Systems. There is a section about focus areas for digital health in health systems and hospitals. The most active health systems are partnering more in diagnosis and have a higher share of digital tools for research. Comprehensive breakout of digital health activities at the Top 10 players: Mayo, Mount Sinai, Cleveland Clinic, Sloan Kettering, Massachusetts General, Northwell, Cedars Sinai, Brigham & Women's, InterMountain. Global breakout of health systems with digital health partnerships at scale. Geographical breakout of digital health partner headquarters (by region). Strong preference for B2B business model. 1/3 of digital health partnerships with Early Stage venture companies. Emphasis is on strong clinical evidence. Portfolio size allows greater diversity. Cluster distribution depends on therapeutic area. Digital health analytics breakout including alpha score, venture similarity score, venture valuation, team signal, partnership signal, evidence signal.
Course Syllabus (Digital Rosh): The Future of Digital Medicine- Biology, Gene...Levi Shapiro
Syllabus for the Future of Digital Medicine course, 2023- Biology, Genetics, Technology and BioInformatics. Includes lectures from Noam Shomron, Michal Rosen-Zvi, Eyal Zimlichman, Gila Tolub, Dana Bar-On, Yesha Sivan, Vladi Dvoryis, Varda Shalev, Avi Schroeder, Christian Tidano, Eyal Toledano.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
4. COMPANY CONFIDENTIAL
As Incentives Align, Informatics Becomes Key to
Addressing Major Needs
Viable OpportunitiesFrom To
Pay for service & provider
incentives to maximize revenue
Focus on what’s broken or
inefficient (adherence, errors,
ineffective treatments, overuse)
Pay for performance and efficiency
Individual components and
products
total solutions, portfolios of products
and services
Risk sharing service models,
startups create key components
Solutions for patients and
providers
Solutions for patients, providers and
payers
Data aggregation and analytics
(big‐data), Population Health
Management Solutions
Cost reduction and Incremental
Innovation
Disruptive, innovations that solves
health‐system level problems
New skills, Bigger Problems
Theoretically Equivalent “Non‐
Inferior” Products
Proven Superior Products (Clinically
Proven)
Proven Superior Products
(Clinically Proven)
Pure focus on clinical outcomes Focus on clinical and economic
outcomes
Drive healthcare delivery efficiency
and optimize processes
Physician preference and custom Data driven, analytically proven, and
standardized
Automation, analytics (CDSS), big
data
Operating Rooms & Hospitals as
primary Revenue Drivers
Operating Rooms & Hospitals as
primary Cost Drivers
Technologies that keep patients out
of the hospital and OR
4
6. COMPANY CONFIDENTIAL
Dave’s (Not So Insightful) Digital Health Predictions
1. Internet of Medical Things/Medical Industrial Internet will fundamentally improve patient
care and reduce costs
2. Connecting well‐care, prevention and sick‐care will align with reimbursement incentives and
consumer interest – but behavior change and fundamental differences in well‐care/sick‐care
industry dynamics will slow change
3. Big Data will revolutionize healthcare, but generating and leveraging “the right”, real‐time
data will drive more immediate value
4. Enhanced access to care (Tele‐Medicine), healthcare process and delivery automation
(Kiosks) and the democratization of healthcare knowledge (digitized care paths) will drive
care delivery toward lower costs professionals and patients themselves
5. The comprehensively digitized and individualized patient (wearable tech, genomics, etc.) will
enable personalized/customized medicine at “mass‐produced” cost.
6. Care coordination across care teams (patient, family, retail, nurse, physician,), care sites
(home, retail, acute) and along the continuum of care (wellness to monitoring) driven by
connectivity and digital care plans, will identify tremendous opportunities for improved care
which will be gradually addressed by broad‐based “solutions”
7. Healthcare best‐practices and clinical guidelines will be more defined by looking backward at
robust historical data than looking forward at prospective clinical trials. Watson, Explorys,
etc. will identify broad opportunities for healthcare efficiency improvement.
8. • Enabling safer, simpler and more effective
parenteral drug delivery
• Improving clinical outcomes through new, accurate
and faster diagnostics;
• Providing tools and technologies to the research
community that facilitate basic science, drug
discovery and cell therapy;
• Enhancing disease management in diabetes,
women’s health and cancer, and infection
control.
• Improving clinical, laboratory and research
practices in emerging markets
Strategy and Focus Areas
Drive revenue
growth through
investment in
innovation
BD’s Strategy is to Apply Technology and Clinical Knowledge
to Make Healthcare More Effective, Efficient and Safe.
The Five Areas of Focus Are:
BD’s Strategy is to Apply Technology and Clinical Knowledge
to Make Healthcare More Effective, Efficient and Safe.
The Five Areas of Focus Are:
9. 9
BD SafetyGlide™
Injection Needle
BD Nexiva™ Closed IV
Catheter System
BD PosiFlush™
Heparin-filled Flush Syringe
BD Soluvia™ Prefillable
Microinjection System
Enabling safer, simpler and more effective
parenteral drug delivery
BD Emerald™ Syringe
BD Sterifill Advance™
Plastic Prefillable Syringe
Insert BD
Simplist here
BD Simplist™ line of
ready-to-administer
prefilled injectables
10. Improving clinical outcomes through new,
accurate and faster diagnostics
10
BD Viper™ System
with XTR Technology
BD MAX™ System
BD FocalPoint ™ GS
Imaging System
BD Kiestra™ Total Lab Automation
BD Veritor™ System
BD BACTEC™ FX
11. 11
Providing tools and technologies to the research community
that facilitate basic science, drug discovery and cell therapy
BD FACSVerse™ Analyzer
BD™ LSR II
BD FACSCanto II™
Flow Cytometer
BD Accuri® C6 Flow Cytometer
BD FACSCount™ SystemBD LSR Fortessa™
Cell Analyzer
Research Technologies Clinical Technologies
BD FACS Jazz™
BD FACSCalibur™
BD FACS™ Lyse Wash
Assistant
12. Enhancing disease management in diabetes,
women’s health and cancer, and infection control
12
BD Viper™ System
with XTR Technology BD BACTEC™ FX
Women’s Health and Cancer Infection Control and Patient Safety
BD PosiFlush™
Heparin-filled
Flush Syringe
BD SurePath™
PAP Collection System
Diabetes Care
BD Ultra-Fine™ Nano 4mm
Pen Needles with
PentaPoint™ Comfort
BD AutoShield™ Pen Needle
14. ConfidentialConfidential
BD TO ACQUIRE CAREFUSION FOR $12.2 BILLION
Combination of Complementary Portfolios Creates
Global Leader in Medication Management and
Patient Safety Solutions
Accelerates BD’s Strategy to Improve Quality of
Care and Reduce Healthcare Costs; Enhances
Emerging Market Growth Opportunities
Generates Significant Value for Shareholders;
Accretive to Cash EPS on a Double-Digit
Percentage Basis in the First Full Year
14
16. COMPANY CONFIDENTIAL
The Combined Product Portfolios Would Enable an End-to-End
Medication Management Solution from Pharmacy to Patient
Coronado Portfolio
BD Portfolio
1
6
21. ConfidentialConfidential
What’s Next …
21
“Link Diagnosis and Care Delivery to Solve Health System Problems
and Improve the Lives of Individual Patients”
“Link Diagnosis and Care Delivery to Solve Health System Problems
and Improve the Lives of Individual Patients”
BD’s Medical Internet of Things!BD’s Medical Internet of Things!
Personalized Health System
Level Solutions
(Reduce Cost & Improve Outcomes)
Personalized Health System
Level Solutions
(Reduce Cost & Improve Outcomes)
22. ConfidentialConfidential
Entrepreneurship
(Medical Robotics Startup)
ProductsProducts
David Feygin, VP Health IT Integration & Strategic
Innovation (Former VP Corporate Strategic Innovation)
22
Deep Technical &
Medical Understanding
(Ph.D. in Medical Robotics)
ScienceScience Slides!Slides!
Commercial Strategy &
Innovation
(MBA & Business Strategy)
I am driven to create new understanding, new products and
new enterprises that dramatically improve people’s livesCommon Thread:
24. Unfortunately, BD Has Not Been Able to Capture Such High Value
Opportunities Outside Our Core…but Change is Coming!
Comprehensive
Examination
• Leading Growth and Innovation Course
• Growth Leader Panel
• GM Accelerator Innovation Diagnostic
• Innovation Profile
Consistent
Diagnosis
Significant Gaps
•Bias toward home court when competing w/innovations
•Insufficient, dedicated resources for synthesis
•No innovation process or funnel (ideas have no pathway)
•No accountability for innovation
•Risk averse & inwardly focused behaviors
Clear Prescription
BD Innovation Work
System
•Search, Synthesis, Select & Execution
•BU, Regional & Corporate Systems
•Innovation clearinghouse enables oversight
and like vs. like comparisons
•Dedicated corporate group accountable for
innovation system and search/synthesis of
white space opportunities
24
25. Purpose of our BD Innovation System
25
Outside the Home Court
Home Court
The BD Innovation System:
• Provides a clear path for outside‐the‐home‐
court innovation that leads to solutions
beyond our core
• Enables us to search for opportunities,
synthesize ideas into innovation, select
innovations for greatest impact, and
execute innovation
26. Why do we need an Innovation System?
26
• Today, the healthcare industry is changing
in fundamental ways
Upgrades to BD’s core products not
sufficient to completely achieve our
desired growth aspirations
Need outside‐the‐home‐court
innovation as well
• Established structures, behaviors, and
processes acting like “prevailing winds”
against efforts to seek and pursue outside‐
the‐home‐court innovation
Need different structures, behaviors,
and processes to support outside‐the‐
home‐court innovation
Outside the Home Court
Home Court
27. What is the BD Innovation System?
27
• New Accountable Structures, new
Behaviors and Culture, such as Constructive
Challenge, and a new rigorous yet dynamic,
multi‐stage Innovation Process
• The Step 5 Coalition is our leadership
change network that will build critical
awareness and make connections across BD
• Implementation is already well underway
28. Accountable Structures, Customer Centricity, Innovation Process,
Cultural Change and “Network Based” Change Enable OTHC Innovation
28
Red Teams
Negative Experts
Functional Challenge
Rules of Challenge
Robust Innovation Process & Portfolio
BDX Innovation Council Strategic Innovation Groups
Established OSMT
Constructive
Challenge
Accountable
Structures
Leadership Change
Network
BDT “Innovation Center”
6 BU Innovation systems
Execution Leads
Shared Value
Europe
Innovation
BD Tech
HR/Talent
Synthesis
Leads
Asia
Innovation
Policy/Regulatory
& Medical
R&D &
Science
Bus‐Dev/Corp‐Dev
Finance
IP and
Legal
BU Strategic
Marketing
HEOR
CSIG, Strategic
Innovation Leads
Emerging Regional Innovation Systems
Step
5
Coalition
29. 29
Innovation System – Idea Journey
Manages the entire BD Innovation Portfolio
BDX
Innovation Council
BU/Regional
Innovation Council
Strategic
Innovation
Leader
BDT
Corporate
Strategic
Innovation
Group
Medical
Strategic Marketing
HEOR
R&D
Regulatory
Transitional or Adjacent Spaces Outside Business and Regional Efforts or Cross‐Business Initiatives
Idea
2
Idea
1
X‐Functional Support & Challenge
31. 31
Innovation System – Idea Synthesis
Market Analytics
Market sizing, segmentation, pricing, trending, primary,
secondary market research Market creation strategies
Portfolio approach , sustainable differentiation, stakeholder
Analysis, EcoSystem Analysis
Business Development
Relationship management, diligence, negotiating & deal structuring, external partner management
Global Sensing/Sourcing
Angel Networks, VC connections, Investor
conferences, regional sensing/sourcing
External Associations
to Understand Problems
KOL relationships, Research Centers,
Universities
Macro‐economic, Policy,
Market, Clinical Trends
Macro Trend Analysis
Health Economics Assessment Including Market Development
Identify large cost areas … cost‐benefit, comparative effectiveness …. market development studis/trials
Policy/Regulatory Changes
Alignment of incentives, regulatory paths, reimbursement,
establishment of regulatory barriers to entry, policy influence, etc.
Concept Development
Consolidated business plans,
Evaluation of novel concepts
X‐Functional Innovation Synthesis
32. Corporate Strategic Innovation Group
(CSIG)
32
Responsibilities
• Shares responsibility for innovation performance with BD Innovation Council
• Engages on selection of innovations
• Implements support and challenge systems
• Manages innovation funnel
Cross Business & Outside the Core
Search & Synthesis
Center Of Excellence
for Innovation
Ownership of BD
Innovation System
• Support Business Unit implementation of
Innovation IIG to synthesize or execute a >$250M
top‐line innovation
• Coordinate global Search & Synthesis
• Track innovation performance metrics
• Drive Search, Synthesize, Select excellence
• Work with Business Unit Innovation
Systems (Cells, Councils, etc.) to implement
and coordinate best‐practices
• Develop white space and cross business opportunities
• Ensure constant flow of innovation opportunities that enable long term
growth by moving the company into new growth markets
34. BD Locations
Industrialized Markets
Emerging Markets
Latin America - 1952
• ~5,200 Associates
• 8 Countries, 5 Plants
U.S.A. - 1897
• ~12,000 Associates
• 29 Plants
•
Canada - 1951
• ~550 Associates
• 1 Plant
Asia Pacific - 1971
• ~4,600 Associates
• 16 Countries, 5 Plants
India - 1995
• ~550 Associates
China - 1994
• ~2,200 Associates
Europe - 1952
• ~6,000 Associates
• 21 Countries, 10 Plants
•
Japan - 1971
• ~600 Associates
• 1 Plant
•
EMA - 1994
•~ 250 Associates
• 10 Countries
*note: last updated April 2013
35. 35
BD Foundation: Our Purpose and Values
“Helping all people live healthy lives”
We treat each other with respect
We do what is right
We always seek to improve
We accept personal responsibility
36. 36
The “Three Greats”
Great performance for customers and shareholders
Great contributions to society
Great place to work
37. FY 2013 Revenues: $8.054B
BD Biosciences
$1.1B
BD Medical
$4.3B
BD Diagnostics
$2.7B
By Segment: By Geography:
38. 38
BD Medical
Focuses on providing innovative solutions to reduce the spread of infection,
enhance diabetes treatment and advance drug delivery.
Customers Served
• Hospitals and clinics
• Physicians’ office practices
• Consumers and retail pharmacies
• Governmental and nonprofit public health agencies
• Pharmaceutical companies
• Healthcare workers
Products
• Needles and syringes
• Intravenous catheters
• Safety-engineered and auto-disable devices
• Prefillable drug delivery systems
• Prefilled IV flush syringes
• Insulin syringes and pen needles
• Regional anesthesia needles and trays
• Sharps disposal containers
• Closed-system drug transfer devices
• BD Simplist™ line of ready-to-administer prefilled injectables
• Medication workflow solutions
39. 39
BD Diagnostics
Focuses on improving quality, increasing productivity and ensuring flexibility to help
laboratories guide medical decisions.
Customers Served
• Hospitals, laboratories and clinics
• Reference laboratories
• Blood banks
• Healthcare workers
• Public health agencies
• Physicians’ office practices
• Industrial and food microbiology laboratories
Products
• Integrated systems for specimen collection
• Safety-engineered blood collection products and systems
• Automated blood culturing systems
• Molecular testing systems for infectious diseases and women’s health
• Microorganism identification and drug susceptibility systems
• Liquid-based cytology systems for cervical cancer screening
• Rapid diagnostic assays
• Plated media
• Microbiology laboratory automation
40. 40
BD Biosciences
Focuses on continually advancing the science and applications
associated with cellular analysis.
Customers Served
• Research and clinical laboratories
• Academic and government institutions
• Pharmaceutical and biotechnology companies
• Hospitals and reference laboratories
• Blood banks
Products
• Fluorescence-activated cell sorters and analyzers
• Monoclonal antibodies and kits for cell analysis
• Reagent systems for life science research
• Cell imaging systems
• Cell culture media and supplements for
biopharmaceutical manufacturing
41. 41
FY2013 Shared Value Outreach
• Pursue our purpose through long-standing relationships with non-governmental
organizations.
• Corporate grants, product donations,
volunteer service initiatives and disaster relief
programs
• Donate time, technical expertise and resources
• Contributions: ~$11 million
– Product donations: $5.1 million (fair market value)
– Cash support: >$5.9 million, including $940,000
in matching gifts
42. 42
FY2013 Shared Value Outreach
Associate engagement programs:
– International volunteer opportunities:
• BD Volunteer Service Trip Program
• BD/PEPFAR Lab Strengthening and Safe Blood Collection Programs
– Henry P. Becton Volunteer Impact Awards Program
– Paid-time off for Volunteer Community Service hours (U.S.)
– U.S. Matching Gifts Program: $940,000 to match associate giving
43. 43
FY2013 – Top Corporate Contributions*
1. AmeriCares*
2. Catholic Medical Mission Board*
3. Heart to Heart*
4. Project HOPE*
5. Direct Relief International*
6. National Cancer Coalition*
7. U.S. Fund for UNICEF
8. Joint Commission’s Center for
Transforming Healthcare
9. GHESKIO TB Hospital, Haiti
10.Accordia Global Health
Foundation